People Willing to Trade Treatment Efficacy for Reduced Side Effects in Cancer Therapies

New research also indicates that cost may override both factors for patients with most prevalent type of leukemia

(WASHINGTON, November 21, 2017) — When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology (ASH). The study also suggests that factoring out-of-pocket costs into this decision-making process may significantly influence a patient’s choice of treatment.

The most prevalent form of leukemia, CLL affects approximately 130,000 people in the United States, and more than 20,000 new cases are diagnosed each year. As more treatment options have been approved in recent years, each with its own associated benefits, side effects, and price tag, patients are forced to weigh many factors when determining their treatment plan.

To gain insight into how patients with CLL balance these differences, lead study author Carol Mansfield, PhD, of RTI Health Solutions, collaborated with the Leukemia & Lymphoma Society, the Lymphoma Research Foundation, and Genentech to conduct a survey among 384 people with CLL. In this discrete choice experiment, patients were asked to choose between hypothetical treatment options, each of which was defined by five variable attributes — progression-free survival, mode of administration, typical severity of diarrhea, chance of serious infection, and chance of organ damage.

“While every patient wants the most effective drug with the fewest side effects, most people don’t have that option available,” said Dr. Mansfield. “By asking patients to make tradeoffs and rank their preference, we can form an understanding of how patients approach their treatment.”

The results of the study show that effectiveness of the drug was the most important factor for participants. Avoiding serious adverse events was also highly valued. On average, a gain in 36 months of progression-free survival was needed for patients to accept a 30 percent risk of serious infection. Least important to respondents was the mode of administration: patients were only willing to trade a few months of efficacy for a more convenient dosing method (oral administration).

"This research brings home the point that each patient has unique circumstances and choosing the right treatment means weighing the different efficacy profiles and side effects against the patient’s priorities,” said Dr. Mansfield. “A successful outcome can be different from one individual to the next, and the outcome they desire depends on their circumstances.”

When the researchers conducted a supplemental cost analysis, they found that out-of-pocket cost had a dramatic impact on the choices respondents made. In a follow-up question giving participants the choice between two medicines with different costs, up to 65 percent of respondents changed their choice of medicine.

“We used the results from the discrete-choice experiment to forecast the probability that a respondent would pick each hypothetical drug without any mention of cost and then compared that to the choices people made when out-of-pocket costs for these medicines were included,” said Dr. Mansfield. “Cost is clearly something that has an impact. When patients get prescribed something they can’t afford, they have to make very difficult choices.”

Ultimately, findings from discrete-choice experiments like this one will help doctors and patients focus on treatments that account for a patient’s unique circumstances and goals. “Patients don’t always know that they could be making these tradeoffs,” said Dr. Mansfield. “We hope that our findings can help doctors to have frank discussions with their patients about the differences between treatments and how these might affect their lives.”

The American Society of Hematology (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal.

Contact: 
Stephen Fitzmaurice, American Society of Hematology
[email protected]; 202-552-4927